Neoclease

About

Neoclease is a biotechnology company pioneering AI-designed gene-editing therapies optimized for individual genes. Using a proprietary platform that integrates generative protein models with synthetic biology, Neoclease builds ultra-precise, delivery-ready nucleases for diseases with high unmet need. Its lead program targets LRRK2 to halt progression of Parkinson’s disease. Neoclease’s approach enables the development of editors with enhanced specificity, efficiency, and size, unlocking new possibilities across thousands of genetic diseases.

Product

Value proposition

Precision Gene Editing with AI to design custom nucleases for targeted gene therapies, aiming to improve lives and accelerate advancement in gene editing

Founders

• Chelsea Trengrove — CEO and Cofounder
• Jin Liu — CTO and Cofounder
• Vivek Gowda — Co-Founder

Categories

Products

Key features

Technologies

Target conditions

Partnerships

News

• MilliporeSigma Announces Neoclease as Winner of 2025 NorthAmerican Advance Biotech Grant · 2025-06-19T05:26:52.000Z
• MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant · 2025-06-18T08:07:29.000Z
• MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant · 2025-06-18T00:00:00.000Z
• MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant · 2025-06-18T12:00:00.000Z
• Neoclease Awarded Yearlong Residency at The Engine Following AgingCode Summit · 2025-06-14T05:20:23.000Z
• Neoclease Joins the LabCentral AI BioHub in Partnership with C10 · 2025-07-01T07:00:00.000Z

Browse related software

• Clinic software in MA
• Clinic software in Boston
• BioTech software
• Genomics software
• AI in Healthcare software
• Health AI software
• MedTech software
• All clinic software companies A–Z